CLINICAL TRIALS PROFILE FOR METHOCARBAMOL
✉ Email this page to a colleague
All Clinical Trials for methocarbamol
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02432456 ↗ | Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients | Completed | Medical College of Wisconsin | Phase 4 | 2015-09-01 | This study will evaluate the effectiveness of ketamine infusions in the management of acute pain resulting from broken ribs suffered following a blunt trauma. Half of patients will receive the institutional standard of care and a placebo infusion (no active medication). The other half of patients will receive the institutional standard of care and a ketamine infusion. All subjects and staff will be blinded as to whether they are receiving placebo or ketamine. |
| NCT02642874 ↗ | Methocarbamol in Treatment of Muscle Cramps in Cirrhotic Patients | Unknown status | Tanta University | Phase 3 | 2017-04-01 | Muscle cramps markedly affect the quality of life in cirrhotic patients with no highly effective drug. Methocarbamol is a central muscle relaxant used to treat skeletal muscle spasms. The mechanism of action of methocarbamol is currently unknown, but may involve the inhibition of carbonic anhydrase. Methocarbamol has a high therapeutic index, i.e. a wide range of safe and effective dosages. |
| NCT02665286 ↗ | Orphenadrine and Methocarbamol for LBP | Completed | Montefiore Medical Center | Phase 4 | 2016-03-01 | Low back pain is a common cause of visit to emergency department. It is not clear if skeletal muscle relaxants are of benefit for patients with acute low back pain. This is a randomized study to determine if skeletal muscle relaxants, when combined with naproxen, improve outcomes more than naproxen alone |
| NCT02831569 ↗ | Japanese IP-TN Trial | Completed | SSP Co., Ltd. | Phase 3 | 2016-07-27 | This is an open-label, single-group, multi-centre trial to confirm the safety and efficacy of loxoprofen sodium/methocarbamol ( IP-TN) when administered orally for 2 weeks to patients with low back pain, scapulohumeral periarthritis, or cervico-omo-brachial syndrome associated with muscle strain. More than 90 patients will be screened to enroll approximately 80 patients in the trial. After giving written informed consent, patients will be enrolled in the trial. Patients who are considered eligible for the trial by the Investigator after consent and complete the trial procedures and assessments at Visit 1 will receive the trial medication and enter the open-label treatment period of 2 weeks. Patients who complete the open-label treatment period will enter the follow-up period of 1 week and complete the trial after confirmation at the last visit (or phone interview). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for methocarbamol
Condition Name
Clinical Trial Locations for methocarbamol
Trials by Country
Clinical Trial Progress for methocarbamol
Clinical Trial Phase
Clinical Trial Sponsors for methocarbamol
Sponsor Name
